Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The insulin-like growth factor 2 receptor (IGF2R) IGF2-binding site, primarily located within domain 11 of the receptor's 15 extracellular repeats, is a highly specialized functional region responsible for binding and clearing extracellular insulin-like growth factor 2 (IGF2). By sequestering free IGF2 and directing it to lysosomes for degradation, this binding site acts as a natural tumor suppressor and negative regulator of cell growth. This clearance mechanism prevents excess IGF2 from activating mitogenic signaling through the IGF1 receptor (IGF1R) and insulin receptor isoform A (IR-A). In therapeutic development, this site is exploited in several ways. First, it is targeted by lysosome-targeting chimeras (LYTACs) that use engineered IGF2-based ligands to shuttle membrane-bound or extracellular oncoproteins to lysosomes for degradation. Second, it is utilized in enzyme replacement therapies (such as reveglucosidase alfa) that employ IGF2-derived peptide tags to enhance lysosomal delivery of therapeutic enzymes. Third, it is targeted by monoclonal antibodies (such as IF3) to deliver radionuclides to IGF2R-overexpressing tumors like osteosarcoma. However, targeting this site presents challenges, including the risk of hypoglycemia from off-target activation of IGF1R/insulin receptors by IGF2-based ligands. Additionally, target-mediated drug disposition, such as spleen accumulation, remains a concern due to the ubiquitous expression of IGF2R in normal tissues.
Bifunctional degradation (LYTAC-mediated endocytosis and lysosomal degradation of target proteins), receptor-mediated endocytosis and lysosomal delivery of therapeutic enzymes, sequestration of extracellular IGF2 (soluble receptor traps), and targeted radionuclide delivery (radioimmunotherapy)
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin-like growth factor 2 receptor (IGF2R).